Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: TraderXx who wrote (912)	8/2/1999 4:53:00 PM
From: caly	Respond to of 2515

IMO, you should be in IMCL for future, not present, earnings potential. Although there was this in the last quarterly overview: "At the end of the quarter, ImClone announced that they will receive a $5 million milestone payment from its corporate partner in the development of C225, Merck KGaA of Darmstadt, Germany. The milestone payment is based on the completion of a successful meeting with the U.S. FDA allowing ImClone to initiate a Phase III clinical trial. The Phase III clinical trial will evaluate the effect of C225 in combination with radiation in approximately 416 patients with advanced squamous cell head and neck cancer. Following the close of the quarter, the Company announced that an additional $3 million milestone payment was triggered by the agreement of the U.S. Food & Drug Administration to allow ImClone to initiate a second Phase III pivotal clinical trial of C225. This second Phase III clinical trial will evaluate C225 in combination with cisplatin, a chemotherapeutic agent, in 114 patients with advanced squamous cell head and neck carcinoma."